American Society of Hirudotherapy

Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct)

Investigational adjunct for pain-predominant IBS refractory to dietary and pharmacologic therapy; low-FODMAP diet, antispasmodics, low-dose tricyclic antidepressants, and cognitive behavioral therapy or gut-directed hypnotherapy remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for irritable bowel syndrome, pain-predominant. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for IBS was identified in PubMed or Europe PMC. Evidence-based first-line management is dietary intervention (a limited low-FODMAP trial is recommended in the 2021 ACG guideline (conditional recommendation, very low-quality evidence)), antispasmodics (hyoscyamine, peppermint oil), tricyclic antidepressants or SNRIs for pain, soluble fiber for constipation-predominant subtypes, eluxadoline or rifaximin for diarrhea-predominant or mixed subtypes, gut-directed hypnotherapy, and cognitive behavioral therapy.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Bowel symptom flare around session days from stress and dietary disruption
  • Distraction from evidence-based dietary and pharmacologic interventions
Who should not consider this
  • Patients with alarm features (rectal bleeding, weight loss, anemia, age over 50 without prior workup) — need GI workup first
  • Patients who have not tried low-FODMAP diet, antispasmodics, or appropriate medications
  • Patients with possible inflammatory bowel disease or celiac disease that has not been ruled out
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Have I had appropriate IBS workup excluding IBD, celiac, and other mimics?
  • Have I tried low-FODMAP diet under a dietitian's guidance?
  • Have I tried antispasmodics, peppermint oil, or a tricyclic antidepressant?
  • Have CBT or gut-directed hypnotherapy been considered?
  • What is the published evidence base for leeches in IBS?
  • How will success be measured?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Rectal bleeding, black or tarry stools, unintentional weight loss
  • Nighttime diarrhea waking from sleep
  • Severe abdominal pain not typical of IBS pattern

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for IBS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace low-FODMAP diet, antispasmodics, or psychological therapies.
  • It does not change the gut-brain axis dysregulation underlying IBS.
  • It does not exclude or treat IBD, celiac, or other mimics.
  • No clinical study of leech therapy in IBS was identified, so its effect is unknown.

Clinical Profile

Category
Gastrointestinal
ICD-10
K58.0, K58.1, K58.2, K58.8, K58.9
Safety tier
Medium

Evidence Summary

Irritable bowel syndrome (Rome IV) is recurrent abdominal pain associated with defecation or change in bowel habits, in the absence of structural disease. Pain-predominant phenotypes overlap with IBS-D, IBS-C, and IBS-M. Evidence-based management is dietary trial (low-FODMAP, with structured reintroduction), antispasmodics (hyoscine, peppermint oil), low-dose tricyclic antidepressants for pain, SSRIs for IBS-C with mood comorbidity, and gut-directed hypnotherapy or cognitive behavioral therapy with substantial RCT support. Linaclotide, plecanatide, and lubiprostone for IBS-C; eluxadoline, rifaximin, and alosetron for IBS-D. No clinical study or case report of leech therapy for irritable bowel syndrome was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or Russian- and German-language web searches (searched October 2026), and the 2004 Baskova and Isakhanyan monograph reports none; a popular Russian leech-therapy guide lists irritable bowel among its indications without presenting any data.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Alarm features (weight loss, GI bleeding, anemia, family history of GI cancer) — workup first
  • Inflammatory bowel disease
  • Active gastroenteritis or post-infectious IBS within 8 weeks
  • Stoma, ventral hernia, or abdominal wall pathology at placement site
  • Pregnancy or lactation

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.